Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Ranbaxy: Billion dollar baby! - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Ranbaxy: Billion dollar baby!

May 17, 2006

Ranbaxy has been in the limelight recently after a US court termed the US FDA’s decision ‘unlawful’, opening the door for the lucrative 180-day exclusivity period for ‘Simvastatin’. In this article, we shall take a look at two of Ranbaxy’s first-to-file (FTF) opportunities and the likely impact on revenues, should these opportunities materialise.

Going the Para IV way
Considering the competitive pricing environment prevailing in the US generics market, generic companies are increasingly looking to augment revenue streams by increasing the pace of Para IV filings. That said, the same is fraught with risks, since the benefits from the same depend upon the outcome of litigation, which in turn entails higher legal expenses. While Ranbaxy has been stepping up its Para IV filings, the company is also focusing on Para III filings in a bid to ensure stability in revenues. Investors should note that we have not factored in any upside from these 180-day exclusivities, unless and until the US FDA grants the same.

Ranbaxy's potential FTF opportunities
Generic drug Brand name Indication Innovator Sales (US$ m) Other challengers
Pravastatin Pravachol Cholesterol BMS 1,800 Teva, Apotex and Genpharm
Simvastatin Zocor Cholesterol Merck 5,000 Teva/Ivax
Atorvastatin Lipitor Cholesterol Pfizer 10,000 None
Esomeprazole Nexium Anti-ulcer AstraZeneca 4,633 None
Fenofibrate Tricor Cholesterol Abbott 1,020 Teva, Par and Cipher
Valacyclovir Valtrex Herpes GSK 1,040 None
Pioglitazone Actos Anti-diabetes Takeda   Alpharma, Mylan, Teva and Watson
Tamsulosin Flomax Urology Boehringer 773 None
Source: Ranbaxy presentation, US FDA, Equitymaster research

Pravastatin (Pravachol)
Pravastatin is a blockbuster drug (US$ 1.8 bn in revenues) belonging to the billion dollar statin class (for reducing cholesterol). This drug belongs to the innovator, BMS. It must be noted that the drug went off patent on April 20, 2006 with Teva receiving the 180-day exclusivity on 10 mg, 20 mg, and 40 mg strengths. Ranbaxy is gunning for the 180-day window on 80 mg dosage form and is currently awaiting US FDA approval for the same. The market size of the 80 mg strength is US$ 220 m. In the event that it is granted the 180-day exclusivity and assuming 50% price erosion and a 35% market share, the drug will contribute around US$ 19 m (Rs 836 m) to Ranbaxy’s topline in CY06. Post the exclusivity period, prices will erode at a much faster clip as more players enter the fray.

Simvastatin (Zocor)
Simvastatin is a US$ 5.0 bn dollar a year drug, belonging to Merck and is scheduled to go off patent in June 2006. While Ivax (acquired by Teva) had the FTF claim on the 5, 10, 20 and 40 mg strengths, Ranbaxy has a FTF claim on the 80 mg strength (US$ 500 m in revenues). Teva and Ranbaxy had, however, not challenged the main patent and as a result, were entitled to the 180-day exclusivity after patent expiry of the main compound. With Merck later de-listing the challenged patents, the US FDA refused to grant exclusivity on the same. In recent developments, a US court termed the US FDA’s decision as ‘unlawful’, which means that Teva and Ranbaxy can hope to secure exclusivity on this drug. That said, the US FDA has still to come with a final decision on the issue. It may further be recalled, that Merck had entered into a 180-day exclusivity deal with Dr.Reddy’s for the drug.

Generally, authorised generics tend to garner a higher market share as compared to the challenging company as they have the backing of the innovator. From Ranbaxy’s perspective, in the event of the 180 day exclusivity being granted, and assuming a 50% price erosion and a 35% market share, the drug will contribute around US$ 43 m (Rs 1.8 bn) to Ranbaxy’s topline in CY06.

FTF opportunities in a nutshell
Ranbaxy’s total cumulative ANDAs now stand at 170, with 111 product approvals and the remaining 59 pending approvals. This makes Ranbaxy’s product pipeline the second largest in the US generics market (after Teva), indicating the potential in the long-term. Out of these, 18 are potential ‘first-to-file’ opportunities (FTFs) representing a market size worth US$ 22.2 bn. It must be noted that out of these 18 FTFs, currently 6 are under litigation (including the ‘Lipitor’ suit, which Ranbaxy has lost). The remaining 12 molecules on which Ranbaxy has not been sued represent a market of around US$ 9.7 bn in innovator sales. However, these opportunities, if approved by the US FDA, will unravel over a period of three to five years.

What to expect?
At the current price of Rs 478, the stock is trading at a price to earnings multiple of 20 times our estimated CY07 earnings (without considering Terapia), which is at the higher end of our valuation spectrum. After a forgettable CY05, CY06 and beyond is expected to be relatively better for Ranbaxy. While the pricing pressure in the US is expected to continue in CY06 as well, the company is planning to counter the same on the back of an increased product flow. In addition, the company is undertaking several cost cutting initiatives in a bid to spruce up margins. We shall soon update our research report on the company.

To Read the Full Story, Subscribe or Sign In
To Read the Full Story, Subscribe or Sign In

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms


Apr 1, 2015 (Close)


  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks